Stocktoria
Merck & Co., Inc. MRK
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 1941-01-01
Merck & Co., Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $65.0B | $64.2B | $60.1B | $59.3B | $48.7B |
| R&D expense | $15.8B | $17.9B | $30.5B | $13.5B | $12.2B |
| SG&A expense | $10.7B | $10.8B | $10.5B | $10.0B | $9.6B |
| Interest expense | — | — | $1.1B | $962.0M | $806.0M |
| Income tax | $2.8B | $2.8B | $1.5B | $1.9B | $1.5B |
| Net income | $18.3B | $17.1B | $365.0M | $14.5B | $13.0B |
| EPS (diluted) | $7.28 | $6.74 | $0.14 | $5.71 | $5.14 |
| Operating cash flow | $16.5B | $21.5B | $13.0B | $19.1B | $13.1B |
| Free cash flow | $12.4B | $18.1B | $9.1B | $14.7B | $8.7B |
| Cash & equivalents | $14.6B | $13.2B | $6.8B | $12.7B | $8.1B |
| Inventory | $6.7B | $6.1B | $6.4B | $5.9B | $6.0B |
| Total assets | $136.9B | $117.1B | $106.7B | $109.2B | $105.7B |
| Shareholders' equity | $52.7B | $46.4B | $37.6B | $46.1B | $38.3B |
Source: SEC EDGAR filings · CIK 0000310158 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.